Abstract
Targeting Brutons tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic complications in cancer patients. This review will focus on the role of BTK in drug resistance in cancer, thromboembolism, and various pathologic immune responses, such as graft versus host disease. The therapeutic potential of targeting BTK is illustrated by discussion of the biologic activity profile of the rationally designed BTK inhibitor LFM-A13.
Keywords: Rational drug design, tyrosine kinases, BTK, cancer, thromboembolism
Anti-Cancer Agents in Medicinal Chemistry
Title: Brutons Tyrosine Kinase as a New Therapeutic Target
Volume: 7 Issue: 6
Author(s): Fatih M. Uckun, Heather E. Tibbles and Alexei O. Vassilev
Affiliation:
Keywords: Rational drug design, tyrosine kinases, BTK, cancer, thromboembolism
Abstract: Targeting Brutons tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic complications in cancer patients. This review will focus on the role of BTK in drug resistance in cancer, thromboembolism, and various pathologic immune responses, such as graft versus host disease. The therapeutic potential of targeting BTK is illustrated by discussion of the biologic activity profile of the rationally designed BTK inhibitor LFM-A13.
Export Options
About this article
Cite this article as:
Uckun M. Fatih, Tibbles E. Heather and Vassilev O. Alexei, Brutons Tyrosine Kinase as a New Therapeutic Target, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (6) . https://dx.doi.org/10.2174/187152007784111331
DOI https://dx.doi.org/10.2174/187152007784111331 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Thrombosis in Paroxysmal Nocturnal Hemoglobinuria at a Glance: A Clinical Review
Current Vascular Pharmacology Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology Editorial: New Therapetic Approaches in the Management of Ischemia Reperfusion Injury and Cardiometabolic Diseases: Opportunities and Challenges
Current Drug Targets Latest Advances in Hydrogel-Based Drug Delivery Systems for Optimization of Metabolic Syndrome Treatment
Current Medicinal Chemistry The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Migraine Attack Treatment : A Tailor-made Suit, Not One Size Fits All
Recent Patents on CNS Drug Discovery (Discontinued) PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology Vascular Progenitor Cells in the Development of Transplant Arteriopathy
Current Genomics Stem Cell Therapies for Ischemic Cardiovascular Diseases
Recent Patents on Regenerative Medicine Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry Microvascular Diseases: Is A New Era Coming?
Cardiovascular & Hematological Agents in Medicinal Chemistry Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology NLRP3 Is Involved in Ischemia/Reperfusion Injury
CNS & Neurological Disorders - Drug Targets Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Impact of Dendritic Cells on Vascular Biology
Current Hypertension Reviews Natural Products as a Source of Antiarrhythmic Drugs
Mini-Reviews in Medicinal Chemistry Evidence-Based Percutaneous Closure of the Left Atrial Appendage in Patients with Atrial Fibrillation
Current Cardiology Reviews Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders